<DOC>
	<DOCNO>NCT00386412</DOCNO>
	<brief_summary>PRINCIPAL ENDPOINT To value valganciclovir efficacy advance treatment CMV patient receive allogenic transplant uniform treatment . SECONDARY ENDPOINT To value valganciclovir security advance treatment CMV patient receive allogenic transplant uniform treatment . The security value % patient : Will negative CMV Neutropenia &lt; 1000 neutrophils/mm3 &lt; 500 neutrophils/mm3 first 35 day treatment - follow-up Renal toxicity first 35 day treatment - follow-up ( define elevate creatinine &gt; 1mg/dL twice basal value ) CMV illness treatment next 2 month Blood Antigenemia / PCR positive next 2months treatment This date Hill compare patient control group treat intravenous valganciclovir</brief_summary>
	<brief_title>TAMOVALCIR Allogenic Hematopoietic Progenitors Transplant</brief_title>
	<detailed_description>Clinical trial drug new condition use</detailed_description>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>Patients &gt; 18 year old Any patient allogenic TPH Following postTPH antigenemia PCRCMV CMV blood test detect antigenemia PCR day 180 postTPH The beginning treatment must Duch early possible . Maximum 72 hour antigenemia PCRCMV detection Be first second time CMV infection Sign inform consent Pregnancy negative test fertile age patient Patients received auto syngenic TPH Patients &lt; 50 kg weight Known allergy hypersensibility patient valganciclovir , ganciclovir aciclovir Digestive intolerant : nauseous , vomit diarrhea could difficult oral administration valganciclovir Patients present CMV infection evaluate suspected CMV Patients present &gt; 2 CMV infection episode , current one Severe liver disease define bilirubin ≥ 10mg/dL Treated : foscarnet , ganciclovir , cidofovir another antiviral drug active CMV , previous 30 day current episode Neutrophils &lt; 500 /µL begin valganciclovir treatment . Patients &gt; 500 PMN/µL &lt; 1000/µL must start GCSF treatment get neutrophil value &gt; 1000/µL Platelets &lt; 25/mm3 even receive transfusion Clearance Creatinine &lt; 10mL/min dialyse patient Pregnancy lactant woman Other contraindication detail `` filling card '' Previous inclusión study treat group . Is allow patient participate control case receive valganciclovir treatment CMV episode</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Cytomegalovirus infection</keyword>
</DOC>